REVB
REVELATION BIOSCIENCES, INC.
Next earnings Aug 6, 2026 · consensus $-0.85 EPS
Last earnings +0.0% on 2026-05-07
$1.08
▲ +3.85%$1.08▼ -88.00%
over 1Y
L $0.96H $12.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.8%
1W+12.5%
1M+1.9%
3M-13.6%
YTD-66.8%
1Y-88.0%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 7 analysts
Buy
Going-concern clinical-stage biopharma with no revenue, sub-1yr cash runway, and 311% share dilution — uninvestable, not cheap.
Cash & equivalents $10.7M · FY2025
Revelation is a pre-revenue, clinical-stage biopharma whose entire value rests on two unapproved kidney-disease programs (GEM-AKI and GEM-CKD) built on its Gemini/PHAD TLR4-agonist formulation. There are no products approved for sale, the company has 'never generated revenue,' and management itself states revenue is 'at least several years, if ever' away. Cumulative losses have driven a $49.4M accumulated deficit against just $8.86M of equity, and ROE is -100.6% — the business consumes its entire capital base annually.
The decisive fact is management's own going-concern warning: even with ~$10.7M cash at year-end 2025 plus ~$6.7M of net proceeds from the January 2026 warrant-inducement deal, they explicitly say this 'will not be sufficient to sustain operations within one-year after the date that our audited financial statements... were issued.' With operating cash flow of -$8.27M in FY2025, that runway is razor-thin, and the stated plan is to plug the gap through more public/private equity or debt — i.e., further dilution on 'terms that may adversely affect' existing holders.
Is REVB a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~90d expiry
- Long put 1 @ ~0.09 est
- Short put 1 @ ~0.09 est
debit $0max +$0max $0
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.0M | -$10.9M | -$8.66M | -$7.98M | -$9.07M |
| Net income | -$12.0M | -$10.8M | -$120K | -$15.0M | -$8.91M |
| Diluted EPS | -$42.50 | -$149.20 | -$8.44 | -$1,052.16 | -$23.95 |
| Net margin | — | — | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$6.48M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-211.2%
FCF yield-196.4%
Quality & risk
ROIC (est.)-80.9%
Free cash flow-$8.29M
Total debt—
Net cash$10.7M
Piotroski F-Score3/6
Capital returns
Buyback yield841.0%
Dividend yield (est.)—
Shareholder yield841.0%
Shares Δ YoY+311.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Officer / director change2026-06-24
Annual meeting: board/officer changes, bylaw/charter amendment approved by holders
- 8-K Other event2026-06-01
Item 8.01 other-events corporate update; no direct financial impact disclosed
- DEF 14A Proxy statement2026-05-11
DEF 14A proxy for annual meeting; routine governance/board-election items
- 8-K Earnings results2026-05-07
Q1 2026: ongoing losses and cash burn; going-concern doubt persists
- 10-Q Quarterly report2026-05-07
Q1 2026: ongoing losses and cash burn; going-concern doubt persists
- 8-K Material event2026-03-19
Special-meeting vote modified security-holder rights (share-authorization change)
- 8-K Earnings results2026-02-26
FY2025 10-K: substantial going-concern doubt; cash insufficient for 12 months
- 10-K Annual report2026-02-26
FY2025 10-K: substantial going-concern doubt; cash insufficient for 12 months
- DEF 14A Proxy statement2026-02-17
DEF 14A special-meeting proxy; likely share-authorization/dilution approval
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-242026-06-24open ↗8-KPeriod ending 2026-06-012026-06-01open ↗SCHEDULE 13GFiling2026-05-15open ↗DEF 14APeriod ending 2026-06-242026-05-11open ↗ARSPeriod ending 2026-05-112026-05-11open ↗8-KPeriod ending 2026-05-072026-05-07open ↗10-QPeriod ending 2026-03-312026-05-07open ↗4Period ending 2026-04-302026-05-01open ↗4Period ending 2026-04-302026-05-01open ↗PRE 14APeriod ending 2026-06-242026-04-30open ↗S-8Filing2026-04-15open ↗8-KPeriod ending 2026-03-182026-03-19open ↗
Frequently asked
- Is REVELATION BIOSCIENCES, INC. (REVB) a buy?
- REVB currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Going-concern clinical-stage biopharma with no revenue, sub-1yr cash runway, and 311% share dilution — uninvestable, not cheap.
- What is REVELATION BIOSCIENCES, INC.'s quality score?
- REVB scores 52.67181174089069/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001810560, latest 10-Q filed 2026-05-07) · EODHD · Proprietary analysis · as of 7/4/2026, 10:11:43 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:11 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.